Neurocrine Biosciences initiated its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1117567 in healthy adult participants. NBI-1117567 is an investigational, oral, M1/M4 selective muscarinic agonist for the potential treatment of neurological and neuropsychiatric conditions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine presents data from CAHtalyst Pediatric Phase 3 clinical study
- Neurocrine price target raised to $150 from $140 at Citi
- Neurocrine price target raised to $164 from $154 at Canaccord
- Neurocrine price target raised to $216 from $200 at Oppenheimer
- Neurocrine price target raised to $169 from $150 at Barclays